Mobility Center
Akzo Nobel to Invest NLG 70 Million in aPharmaceutical Ingredient Plant.
ARNHEM, Netherlands--(BUSINESS WIRE)--July 2, 1998--Akzo Nobel N.V. will invest NLG 70 million (USD 35 million) in a new plant for its business unit Diosynth in Oss, the Netherlands. The new plant will have a surface of about 6,000 square meters and is expected to become operational in the year
ARNHEM, Netherlands--(BUSINESS WIRE)--July 2, 1998--Akzo Nobel N.V. will invest NLG 70 million (USD 35 million) in a new plant for its business unit Diosynth in Oss, the Netherlands. The new plant will have a surface of about 6,000 square meters
Diosynth, a business unit of Akzo Nobel, is specialized in the production of complex active ingredients used in the global pharmaceutical industry, including Akzo Nobel's business unit Organon. The company will build new, state-of-the-art facilities as many medicines can only be manufactured in highly specialized installations. Under strictly controlled conditions, in so called clean rooms, new biotechnological products, peptides and saccharides will go through final steps, including purification.
"This is a very important investment for us," said Johan Evers, General Manager of Diosynth. "Not only does it enable us to meet the increasing demand for new products but it also allows us to anticipate technological developments".
"We also hope that this investment will stimulate the Dutch government to improve the climate for innovation," said Evers. "New medicines are in principle not allowed to be introduced in the Netherlands. It would be motivating, also for our employees, if the Netherlands would open up again".
Diosynth employs about 2,000 people, of which about 1,400 work in the Netherlands. Diosynth is a business unit of Akzo Nobel. Akzo Nobel, headquartered in Arnhem, The Netherlands, is a market driven and technology based company, serving customers throughout the world with healthcare products, coatings, chemicals, and fibers. The company employs 70,000 people and has activities in 60 countries. In 1997, consolidated sales aggregated $12 billion (24.1 billion NLG). In North America the company employs more than 9,000 employees and has annual sales of approximately $3 billion. The company's ADRs are traded on NASDAQ under the AKZOY symbol. (USD 12 billion).
CONTACT: Diosynth
Johan Evers, tel. +31 412 662223
Note - for the editor/not for publication
URL: http://www.akzonobel.com
Diosynth, a business unit of Akzo Nobel, is specialized in the production of complex active ingredients used in the global pharmaceutical industry, including Akzo Nobel's business unit Organon. The company will build new, state-of-the-art facilities as many medicines can only be manufactured in highly specialized installations. Under strictly controlled conditions, in so called clean rooms, new biotechnological products, peptides and saccharides will go through final steps, including purification.
"This is a very important investment for us," said Johan Evers, General Manager of Diosynth. "Not only does it enable us to meet the increasing demand for new products but it also allows us to anticipate technological developments".
"We also hope that this investment will stimulate the Dutch government to improve the climate for innovation," said Evers. "New medicines are in principle not allowed to be introduced in the Netherlands. It would be motivating, also for our employees, if the Netherlands would open up again".
Diosynth employs about 2,000 people, of which about 1,400 work in the Netherlands. Diosynth is a business unit of Akzo Nobel. Akzo Nobel, headquartered in Arnhem, The Netherlands, is a market driven and technology based company, serving customers throughout the world with healthcare products, coatings, chemicals, and fibers. The company employs 70,000 people and has activities in 60 countries. In 1997, consolidated sales aggregated $12 billion (24.1 billion NLG). In North America the company employs more than 9,000 employees and has annual sales of approximately $3 billion. The company's ADRs are traded on NASDAQ under the AKZOY symbol. (USD 12 billion).
CONTACT: Diosynth
Johan Evers, tel. +31 412 662223
Note - for the editor/not for publication
URL: http://www.akzonobel.com
In addition, make sure to read these articles:
- Base Ten Systems Receives Purchase Order for First TwoAkzo Nobel Pharma Manufacturing...
- Akzo Nobel's Business Diosynth Signs Long-Term Supply Contract with Pfizer.
- Eka Chemicals Acquires Korean Paper ChemicalsBusiness.
- Akzo Nobel to sell its European Sulfur Productsbusiness to PVS Chemicals.
- Akzo Nobel Sells U.S. Injection Moulding PlasticPackaging Business.
- Akzo Nobel Declares Offer for Courtaulds WhollyUnconditional.
- Akzo Nobel Commences Compulsory Acquistion Procedurefor Outstanding Courtaulds Shares.
- Akzo Nobel to Further Restructure European SurfactantsBusiness.
- Akzo Nobel Chemicals Buys Hampshire Chemical'sU.S. Chelates Business.
- Akzo Nobel to Buy Elementis Stake in AkcrosChemicals.
- Akzo Nobel Strengthens its Position inColombia.
- Akzo Nobel Set to Sell ROVIN Stake toShin-Etsu.
- Akzo Nobel Polymer Chemicals Buys Daejin's AmidesBusiness.
- Akzo Nobel acquires Deckel Lack AB, Sweden.
- Akzo Nobel Buys Polish Distributor of CarRefinishes.
Email
Digg It
del.icio.us
Related Resources
Sponsored Links
Site Map | Contact Us | FAQs | About Us | Media Kit | Reprints | RSS Directory | Sign Up for Free Newsletters | Disclosure Policy
Copyright © 1999 - 2008 AllBusiness.com, Inc. All rights reserved.
No part of this content or the data or information included therein may be reproduced,
republished or redistributed without the prior written consent of AllBusiness.com.
Use of this site is governed by our Copyright and Intellectual Property Policy, Terms of Use Agreement and Privacy Policy.
© COPYRIGHT 1998 Business Wire
You may not repost, republish, reproduce, package and/or redistribute the content of this page,
in whole or in part, without the written permission of the copyright holder.
Online Business Database | Online Business Information | Sales and Marketing Solutions | Business Mailing Lists
AllBusiness.com, its parent company D&B, and its affiliates.
